Background: The Sentinel Distributed Database (SDD) is a large database of patient-level
| INTRODUCTION
In this paper, we report on the validity of inpatient diagnosis codes Acute myocardial infarction is a common endpoint in drug safety studies based on administrative health care records. Prior US and non-US validation studies of AMI diagnoses recorded in databases of insurance claims, hospital discharge abstracts, and electronic health records have generally found that principal diagnoses of AMI from inpatient encounters have a high positive predictive value (PPV), typically in the range of 75% to 95%, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and a sensitivity of 60% to 90%. 3, 5, 15, 16 The PPV associated with secondary inpatient diagnoses of AMI, which has been evaluated in fewer studies, has been found to be modestly lower. 7, 15, 16 Since not all AMI cases are identified with algorithms based on the principal diagnosis field only, a common study design dilemma is whether to also use other types of AMI administrative diagnoses (eg, secondary inpatient diagnoses and emergency department diagnoses)
to identify AMIs. While the high PPV of principal inpatient diagnoses for AMI was confirmed by a prior validation study conducted within the SDD, 11 to date, the validity of nonprincipal inpatient AMI diagnoses has not been assessed in the SDD. To provide researchers and other stakeholders with data on the validity of nonprincipal AMI diagnoses within the SDD, we report on the results of a chart validation study of potential AMI cases identified as part of a safety assessment of intravenous immune globulin (IGIV) products.
| METHODS

| Data sources and study population
The administrative health care records and patient medical charts used to identify and validate potential AMI cases came from 13 SDD Data
Partners who participated in the protocol-based Sentinel assessment of thromboembolic events following immunoglobulin administration.
17
Potential cases from the years 2006-2012 were selected for chart review if an inpatient AMI diagnosis code was recorded in the SDD up to 1 month following a nonspecific (ie, polyvalent) IGIV treatment episode. A complete description of the criteria used to select potential cases can be found in Appendix S1. Additional details concerning the design and objectives of the parent study have been described previously. 17 Intravenous immune globulin is used in the treatment of primary and secondary immunoglobulin deficiencies, and a variety of inflammatory and autoimmune disorders (eg, chronic demyelinating polyneuropathy and immune thrombocytopenic purpura). 18 In Table 1 , we provide descriptive information on the patients included in this chart validation study, including their possible indications for IGIV use and major cardiovascular risk factors. These health conditions were defined as previously described in the protocol for the parent study. • Principal and secondary inpatient AMI diagnoses had high PPVs.
• Position-unspecified diagnoses (eg, from a professional claim associated with an inpatient encounter) had a lower PPV (38%).
• Confirmed AMIs recorded as secondary or positionunknown diagnoses were more often due to demand ischemia.
separately from the facility claim. Codes of this type generally come from claims-based Data Partners.
Eligible post-IVIG inpatient encounters with an AMI diagnosis code listed in any position (principal, secondary, or unspecified) were selected for review. For each potential AMI case meeting study eligibility criteria, Sentinel Data Partners were asked to retrieve a medical chart corresponding to the encounter during which the AMI diagnosis was recorded. In this validation report, we restricted the denominator for our PPV calculations to the subsample of potential cases for which we received a chart that was sufficiently complete to determine whether an AMI occurred ( Figure 1 ).
| Chart abstraction
A trained nurse abstractor (L.P., K.P., A.N., or E.R.) reviewed the medical chart(s) associated with the index AMI hospital encounter. The abstractors recorded information concerning symptom onset, relevant clinician notes, results from diagnostic testing including electrocardiograms, echocardiography, cardiac biomarkers, and cardiac catheterization reports, and other factors relevant for the IGIV safety assessment.
| Case adjudication
Completed abstraction forms (and the original medical charts if needed) were reviewed by a single physician adjudicator with relevant clinical expertise (J.G.R., J.O.E., R.K., or S.G.). Based on the documentation available in the charts, potential cases were adjudicated as a
• definite AMI,
• probable AMI,
• possible AMI,
• no AMI, or
• status unknown/insufficient information. For a small number of potential cases, the chart(s) received contained no recorded diagnosis of an acute AMI, no indication that an acute AMI was considered as part of a differential diagnosis, no diagnostic testing, and no symptoms suggestive of a possible AMI.
These cases were flagged by the abstractors and not reviewed by the physician adjudicators due to resource constraints. For these cases, if the chart(s) received included the discharge summary for the index AMI hospital encounter, the potential case was considered to have been miscoded and classified as no AMI. Otherwise, the case was classified as having an unknown status due to chart incompleteness. As a sensitivity analysis, PPVs were recalculated after counting all such patients as false positives.
| PPV calculation
We calculated the PPV of the AMI diagnosis codes identified in the administrative data by dividing the number of confirmed AMI cases (definite, probable, or possible) by the total number of cases for whom a sufficiently complete chart was obtained for the index AMI hospitalization. Potential cases adjudicated as unknown AMI status due to insufficient information were removed from the denominator for the • 20-39 y 6 (6%)
• 40-59 y 28 (27%)
• 60-79 y 51 (50%)
• 80+ y 15 (15%)
Sex
• Female 49 (48%)
• Male 54 (52%)
Possible indication for IGIV use a
• Autoimmune/inflammatory condition 68 (66%)
• Immune deficiency 39 (38%)
• Infection 16 (16%)
• Bone marrow or hematopoietic stem cell transplant 8 (8%)
• Other indication 26 (25%)
Major cardiovascular risk factors a
• Myocardial infarction 23 (22%)
• Angina 40 (39%)
• Atrial fibrillation or flutter 15 (15%)
• Ischemic stroke 6 (6%)
• Peripheral vascular disease 18 (17%)
• Hypertension, uncomplicated 58 (56%) 
| RESULTS
One hundred forty potential post-IGIV AMI cases were identified in the SDD (118 from claims-based Data Partners; 22 from integrated care delivery systems); required charts could be obtained for 103
(74%, see Figure 1 ). Common reasons that charts were unavailable included an inability to map the encounter record in the SDD to patient and provider identifiers required for chart requests, an inability to locate the medical chart corresponding to the requested encounter, and refusal by the health care provider. See Table S1 for a complete list of reasons that charts were unobtainable.
Of the 103 cases for which charts were available, 83 were from claims-based Data Partners and 20 from integrated care delivery systems. The median age of these patients was 65 years; 48%
were female. Based on administrative diagnoses recorded during the 6 months prior, these patients had a high burden of preexisting atherosclerotic cardiovascular disease (22% with prior AMI diagnosis; 39% with angina) and other major cardiovascular risk factors (75% with hypertension; 26% with diabetes). Additional descriptive information on these patients is provided in Table 1 . Table 2 .
While data on suspected AMI etiology were not collected systematically during the adjudication process, the adjudicators noted that a substantial number of the confirmed AMIs (46%) were likely to be type 2 AMIs (ie, attributable to demand ischemia). 20 The majority of these type 2 AMIs occurred in the setting of anemia, respiratory insufficiency, and/or septic shock. Such conditions are more common in certain IVIG user subgroups than in the general population. Demand ischemia was the suspected etiology in 21%, 72%, and 40% of confirmed AMIs with principal, secondary, and unspecified coding positions, respectively.
| Sensitivity analyses
There were 4 cases with incomplete charts and no recorded diagnosis of an acute AMI, no indication that an acute AMI was considered as part of a differential diagnosis, no diagnostic testing, and no symptoms suggestive of a possible AMI. These cases were classified as "insufficient information" because their charts lacked a discharge Table S2 .
In a separate sensitivity analysis, which was performed in the original sample of 89 patients included in the primary analysis, we recalculated PPVs with only definite AMIs counted as true positives. In these analyses, the PPVs were 48% overall (43/89, 95% CI, 38-59%), 63% (19/30, 95% CI, 44-80%) for principal diagnoses, 55% (18/33, 95% CI, 36-72%) for secondary diagnoses, and 23% (6/26, 95% CI, 9-44%) for position-unspecified diagnoses. Subgroup-specific PPVs for this sensitivity analysis are provided in Table S3 .
| DISCUSSION
In this chart validation study, which relied on data from a protocolbased assessment of the risk of thromboembolic events following IGIV treatment, 17 we evaluated the validity of inpatient administrative diagnosis codes for AMI within the SDD. Positive predictive values were high for principal (93%) and secondary diagnoses (88%) and lower for position-unspecified diagnoses (38%). The PPV estimates from our study are broadly consistent with those reported in prior chart validation studies conducted in the United States and Canada over the last 2 decades.
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Previous validation studies have reported that principal inpatient diagnoses of AMI are associated with PPVs of 75% to 95%.
2-10
Between-study variation in these estimates may be attributable to differences in coding algorithms used to identify potential cases, chart validation criteria, patient populations, and coding practices. In an earlier SDD validation study, chart validation was conducted for a random sample of 153 patients with principal inpatient diagnoses of AMI (ICD-9-CM 410.x0 or 410.x1) drawn from 4 Sentinel Data Partners. 11 They reported a PPV of 86% (95% CI, 79-91%), slightly lower than our estimate of 93% (95% CI, 78-99%) for principalposition diagnoses, though not statistically different given the width of our confidence interval.
The main contribution of our study to the existing literature was to provide PPV estimates for secondary and position-unspecified inpatient AMI diagnosis codes recorded in the SDD. Relative to principal diagnoses, PPVs were only slightly lower for secondary diagnoses (88%; 95% CI, 72-97%) in our sample and not statistically different than our estimate for principal diagnoses. However, it was noteworthy that confirmed AMIs coded as secondary diagnoses were more likely to be type 2 AMIs (72%) than were AMIs coded as principal diagnoses (21%). This difference can likely be attributed to the greater severity and complexity of illness among hospitalized patients, as secondary diagnoses may represent conditions that develop during a hospital stay. 19 As noted before, type 2 AMIs may be more common in our sample of IGIV users due to the higher prevalence of hematopoietic dysfunction, infection, and sepsis among some IGIV patient subgroups.
Positive predictive values were significantly lower for positionunspecified diagnoses (38%). In our study, restricting to principal and secondary AMI diagnoses would have improved the overall PPV of the endpoint definition from 75% to 90%, at the cost of missing 10 of 67 confirmed AMIs (15%). In future studies of AMI where chart confirmation of outcome is not possible, investigators may consider excluding position-unspecified diagnosis codes from their endpoint definitions after weighing the trade-off between sensitivity and a higher PPV.
A limitation of our study was that medical charts were unobtainable for 26% of potential post-IGIV cases identified in the SDD. However, the typical reasons that charts were unavailable (eg, unable to link SDD records to patient or provider identifiers) did not give us reason to suspect that our analyzable sample was systematically different than the total set of potential cases identified. Another limitation-referred to above in the discussion of the high prevalence of type 2 AMIs-is that our sample was limited to patients receiving IGIV, and thus may not be representative of the total population of health plan beneficiaries included in the SDD. Insofar as IGIV users are at higher risk of AMI due to a high prevalence of autoimmune/inflammatory disorders, it is conceivable that PPVs would be higher in IGIV users relative to the general population; all other things being equal, PPVs are higher in populations where the outcome is more common. An additional limitation of our study was that each case was reviewed by a single physi- 
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